GERN Geron Bio: Market Value

Geron Corporation (GERN) has developed a unique telomerase inhibitor to combat blood cancer, securing its leadership in the niche through patents and FDA support. The business now relies on commercial sales, marking a transition from a cash-burn era to cash flow growth, which currently stands at 0.63. This price chart on the GURU.Markets exchange reflects the asset's dynamics as the company monetizes Rytelo and updates its R&D pipeline.

GERN Geron: Market Capitalization in the range 07/04/2022 - 11/13/2026

Geron Bio - analytical breakdowns and key metrics (GERN)

- current price and projected stock value:

Stock Price Geron|GERN - Average Forecast Price

- company stock capitalization data:

Market Value Geron Bio|GERN - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Geron|GERN - Accounting Capitalization|Market Value to Book Value Ratio geron.com|GERN - Company Assets

- debt and solvency information:

- business earnings and investment ratios data:

GERN - Company Net Income|Projected Future Earnings Geron Corporation|GERN - Market Cap to Net Income Ratio|Projected Price to Earnings Geron Corp.|GERN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Geron Bio|GERN - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Geron|GERN - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months geron.com|GERN - Earnings per share growth in current year|Earnings growth forecast for next year Geron Corporation

Analysis of all company metrics:GERN (Geron)

The specific nature of Geron Corporation (GERN), with its dependence on clinical trial outcomes, makes its market value extremely sensitive to regulatory news. This indicator, reflecting the product of the share price and the number of outstanding shares, allows for an assessment of the overall scale of the business and the identification of support levels. By analyzing the trajectory of the company's market capitalization, an investor can distinguish a dangerous collapse from a favorable entry point with a minimal risk of overpaying.

Competitor analysis